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platelet aggregation inhibitor, is indicated in high risk cardiovascular patients to prevent
recurrent ischemic events. Therefore, the purpose of this study was to determine the
safety and efficacy of clopidogrel administration initiated in the early postoperative period
after OPCAB.
Methods: 30-day follow-up of 364 OPCAB patients from Jan-June, 2001 was determined
from prospectively collected data. 193 patients received clopidogrel approximately 4
hours postoperatively if chest tube output < 100cc/hr for 4 hours and then daily for 4-6
weeks. Telephone follow-up was made 6 – 12 months after OPCAB in 93% of clopidogrel
and 88% of non-clopidogrel patients. Adverse cardiovascular events were defined as
unstable angina, myocardial infarction, transient ischemic attack, or stroke.
Results: The 193 clopidogrel patients had significantly higher preoperative risk scores
compared to the 171 non-clopidogrel patients: 3-vessel CAD, 62% vs. 50%, prior PTCA,
26% vs. 16%, prior intracoronary stent placement 19% vs. 7%, and CCS angina III-IV,
58% vs. 37%, p<0.02. None of the clopidogrel patients required reoperation for mediasti-
nal hemorrhage. No group differences in mortality were observed at 6 months. For all risk
categories, no differences in adverse cardiovascular events were observed, 3.4% of clo-
pidogrel patients vs. 5.3% for non-clopidogrel patients, p=NS. However, in low risk
patients (CCS angina score <2 and 1-2 vessel CAD), fewer adverse cardiovascular
events occurred in the clopidogrel group, 1/92 (1.1%) vs. 6/73 (8.2%), p=0.045. Gas-
trointestinal bleeding occurred in 2.2% clopidogrel patients vs. 0.7% non-clopidogrel
patients, p=NS.
Conclusions: According to this protocol, OPCAB patients can safely receive clopidogrel
in the early postoperative period without increased risk for mediastinal hemorrhage. Early
clopidogrel administration after OPCAB may be associated with a reduction in short-term
adverse cardiovascular events.
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Background: Extensive work has confirmed the relationship between ischemic mitral
regurgitation (MR) and remodeling of the infarcted left ventricle (LV), which displaces api-
cally the papillary muscles to which the mitral leaflets are anchored. This study was thus
designed to assess whether transplantation (Tx) of skeletal myoblasts could reduce
mitral leaflet tethering and chronic ischemic MR by decreasing endsystolic volumes
(ESV) and reshaping the infarcted wall. Methods: An open-chest infero-basal infarction
was created in 14 sheep, thereby resulting in a MR which progressively developed over
the ensuing 8 weeks. At this time point, sheep were randomly allocated to receive previ-
ously expanded autologous skeletal myoblasts (230 million cells, of which 65% were
myoblasts identified by a positive staining for CD56, n = 7) or to serve as controls receiv-
ing culture medium only (n = 7). All injections were made in multiple sites in the infarcted
posterior bulging wall. 3D echocardiography was used for serial evaluations performed
immediately after infarction, 2 months therafter (preTx) and 2 additional months after Tx.
End points included blinded measurements of the tethering distance between the
ischemic medial papillary muscle tip and the anterior annulus, LV ejection fraction and
stroke volume while 2D echo was used for assessing wall motion score (WMS). Results:
Parameters (mean ± SEM) were similar at baseline and at 2 months between the 2
groups. Two months after Tx (i.e., 4 months post infarction), myoblast Tx was found to
have reduced the progression of ischemic MR (regurgitation volume: 0.7 ± 0.5 vs. 5.7 ±
0.9 mL in controls, p < 0.01), the increase in ESV (30.4 ± 1.2 mL vs. 42.0 ± 2.8 mL in
controls, p < 0.01) and the tethering distance (0.01 ± 0.05 cm vs. 0.44 ± 0.12 cm in con-
trols, p = 0.01). The benefits of myoblast Tx were also evidenced by a lesser decrease of
LV ejection fraction (2.9 ± 1.8% vs. 7.8 ± 1.9% in controls, p < 0.01) and a significant
improvement of the WMS (-0.6 ± 0.03 vs. 0.1 ± 0.01, respectively, p < 0.01). Conclusion:
Tx of skeletal myoblasts may attenuate mild to moderate chronic ischemic MR by
decreasing ESV and reshaping the infarcted LV wall, thereby enhancing valve coaptation.
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Sanderson, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, 
Hong Kong
Timely subthreshold atrial extrastimuli (AE) delivered in the refractory period can prevent
the induction of atrial fibrillation (AF) by another AE delivered in the vulnerable period.
This study aims to investigate the effect of subthreshold stimulation (SS) on atrial effec-
tive refractory period (AERP).
Methods: 14 patients without history of AF (9 male and 5 female, mean age of 51) were
recruited. AERP of right atrial septum was determined after 5 minutes of pacing with 4
different protocols and 3 sets of cycle length (CL) commenced in random order with 10
minutes of washout time between each protocol. Protocols were as shown in table below,
pacing at high right atrium (HRA) and bi-atrial (HRA + coronary sinus) was at twice dias-
tolic threshold. SS was commenced by introduction of an electrical impulse of 2.0msec in
duration and 20mA in amplitude at 50msec after the preceding captured pacing impulse.
The mean of 3 AERP measurements was recorded.
Results: Analysis showed that the pacing protocol but not the CL had significant effect
on AERP. Multiple comparisons showed that the Bi-atrial + SS group had significant
longer AERP than all other groups (protocol 4 versus protocol 1, p< 0.001; versus proto-
col 2, p< 0.021; versus protocol 3, p< 0.002) 
Conclusion: Bi-atrial SS significantly prolonged AERP. It is plausible that because SS is 
relatively localized, the larger the area of atrium receives SS the greater its effect on 
AERP. The study result suggests that bi-atrial SS may be an effective therapy for preven-
tion of AF.
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(IKs) in Cardiac Electrophysiology and Atrial Fibrillation
Hideko Nakashima, Uwe Gerlach, Stanley Nattel, Montreal Heart Institute, Montreal, PQ, 
Canada, Aventis Pharma, Frankfurt, Germany
Background: The role of IKs in cardiac electrophysiology has been controversial: direct
experimental analysis has been limited by a lack of adequate probes. In this study, we
used a highly-selective IKs blocker, HMR1556 (HMR), to evaluate the IKs contribution to
cardiac electrophysiological function and AF maintenance.
Methods: Anesthetized open-chest dogs were studied before and after HMR alone (1
mg/kg IV), HMR plus nadolol 0.5 mg/kg IV, dofetilide alone (D, 0.16 mg/kg IV) or HMR
plus D (H/D).
Results: HMR alone increased atrial (AERP at cycle length, CL, 300 ms, AERP300:
88±11, M±SD, to 105±13 ms, *p<.05) and ventricular (VERP600: 154±14 to 190±32 ms*)
effective refractory period with positive or no frequency-dependence, and increased
sinus node recovery time (SNRT). Beta blockade eliminated HMR effects on AERP
(AERP300: 99±5 to 101±17 ms) and SNRT, but did not alter changes in VERP (VERP600:
177±19 to 211±11 ms*). D prolonged both AERP (AERP300: 92±4 to 143±17 ms*) and
VERP (VERP600: 179±18 to 213±29 ms*) with reverse use dependence. In the presence
of D, HMR effects were significantly increased, e.g. HMR increased AERP300 22±10% vs
control, H/D increased AERP300 29±12%* vs D; HMR increased VERP600 24±19% vs
control, H/D increased VERP600 32±5%* vs D. In addition, Wenckebach CL was not
affected by HMR alone, but was greatly increased by H/D vs D alone. HMR shortened
the duration of induced vagotonic AF (DAF, 1077±198 to 471±339 sec*), an effect abol-
ished by β-blockade. D had no significant effect on DAF (916±216 to 732±243 ms), but H/
D markedly decreased DAF (to 77±73 ms, p<.001).
Conclusions: IKs plays a role in baseline atrial, ventricular and SA node repolarization in
vivo, with atrial and SA nodal effects being dependent on background β-adrenoceptor
stimulation. IKs also plays a role in AF maintenance in the presence of intact sympathetic
tone. IKs effects are particularly important in the presence of reduced repolarization
reserve, as indicated by the synergistic interaction between HMR and D. This constitutes
the first evaluation of the role of IKs for in vivo cardiac electrophysiology and highlights the
distinct profile of IKs vs IKr blockade.
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Background: Cardiac resynchronization therapy (CRT) is indicated for pts with heart fail-
ure and QRS delay. There is no published data evaluating CRT in pts with right bundle
branch block (RBBB). Methods: Data was analyzed at baseline and 6 months in the 501
pts with NYHA FC II-IV heart failure and ICD indications enrolled in the CONTAK CD Trial
(Guidant, Corp). Results: A total of 66/501 (13%) pts had RBBB, 271/501 (62%) had
LBBB and 164/501 (38%) had IVCD. There were no differences in baseline characteris-
tics between RBBB and non-RBBB pts. Unlike non-RBBB pts, RBBB pts did not demon-
strate improvement in symptom status, heart size or LVEF (Table). NYHA FC did not
improve with RBBB pts and the subset of enrolled pts with FC III-IV symptoms also
showed no benefit. Conclusion: CRT may not benefit RBBB pts. A meta-analysis of the
completed controlled trials of RBBB pts is needed to corroborate these findings. Alterna-
tive stimulation sites should be tested in this subset.
AERP±SD(msec)/
CL(msec)
HRA HRA + SS Bi-atrial Bi-atrial +SS
600 218.2 ± 20.0 221.8 ± 20.8 216.8 ± 20.7 242.1 ± 31.8
500 218.6 ± 20.0 224.3 ± 22.2 220.0 ± 24.5 237.9 ± 30.7
400 211.1 ± 24.0 226.8 ± 20.0 225.4 ± 25.5 240.0 ± 32.3
Table
Endpoint Time RBBB CRT/No
CRT, p
Non RBBB CRT/No
CRT, p
V02
(ml/kg/min)
Baseline
6 mo change
13±.5/13±.5
-1±.6/-.1±.6, ns
14±.2/14±.2
1±.3/0±.3, .009
6 min walk (m) Baseline
6 mo change
302±14/302±13
10±18/21±17, ns
320±6/320±6
39±8/13±8, .02
LVIDs (sys/mm) Baseline
6 mo change
54±1/54±1
-1±2/-2±2, ns
59±.5/59±.5
59±.5/59±.5
-4±.7/-.6±.7, < .001
LVEF (%) Baseline
6 mo change
31±1/31±1
2±2/4±1, ns
27±.4/27±.4
6±.8/3±.8, .008
